Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 9/20 | 0.76 |
| ▸ | PIK3CA | P42336 | 8/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | CSNK1D | P48730 | 4/20 | 0.37 |
| ▸ | CSNK1E | P49674 | 4/20 | 0.37 |
| ▸ | CDK4 | P11802 | 1/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | USP7 | Q93009 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11031102 | 0.87 | MTOR (0.77) | MTORPIK3CAALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL2787610 | 0.87 | MTOR (1.00) | MTORPIK3CACSNK1DCSNK1ECDK4 | |
| SCHEMBL756436 | 0.86 | MTOR (0.76) | MTORPIK3CAALDH1A1HTTCSNK1D | |
| SCHEMBL755854 | 0.85 | MTOR (0.71) | MTORPIK3CAALDH1A1CSNK1DCSNK1E | |
| SCHEMBL11028255 | 0.84 | MTOR (0.53) | MTORPIK3CAALDH1A1HTTCSNK1D | |
| Trifluoroacetic Acid SCHEMBL754788 | 0.82 | MTOR (0.62) | MTORPIK3CAALDH1A1CSNK1DLMNA | |
| SCHEMBL752642 | 0.82 | MTOR (0.69) | MTORPIK3CAALDH1A1CDK2LMNA | |
| SCHEMBL751580 | 0.78 | MTOR (0.71) | MTORPIK3CACDK4CDK2USP7 | |
| SCHEMBL760864 | 0.78 | MTOR (0.51) | MTORPIK3CACSNK1DCSNK1E | |
| SCHEMBL754787 | 0.77 | MTOR (0.61) | MTORPIK3CACDK4CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2430013-B1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | AMGEN INC (US) | 2014-10-15 | — | — | EP | claimed |
| US-20120190666-A1 | Heteroaryl Compounds as PIKK Inhibitors | AMGEN INC. (US) | 2012-07-26 | — | — | US | claimed |
| EP-2430013-B1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | AMGEN INC (US) | 2014-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190666-A1 | Heteroaryl Compounds as PIKK Inhibitors | PIK3CA, PIKFYVE, PIK3CD | MTOR 21/4885PIK3CA 1/4885ALDH1A1 4785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.